Thermo Fisher Scientific Completes $2.2 Billion Registered Public Offering of Senior Notes

• 4.6.2020

WilmerHale represented Thermo Fisher Scientific Inc., a multinational biotechnology product development company, in its public offering of $1.1 billion aggregate principal amount of 4.133% Senior Notes due 2025 and $1.1 billion aggregate principal amount of 4.497% Senior Notes due 2030. Both series of notes priced at 100% of principal. The net proceeds of the offering will be used to pay a portion of the purchase price of the previously announced acquisition of QIAGEN N.V and for general corporate purposes. The offering priced on March 23, 2020 and closed on March 25, 2020.

The team consisted of Erika Robinson, Justin Ochs, Julie Hogan Rodgers, Alan Wilson and Jenny Moore.